HPAI Now Endemic in North America — Structural Risk to Poultry Supply Chains Confirmed

▲▲ BIOSECURITY — Signal Intelligence · Global Food Observatory

Overview

The US Centers for Disease Control has confirmed HPAI H5N1 is endemic in North American wild birds, meaning annual seasonal reinfection of commercial poultry flocks is now structurally locked in. The 2024-25 season cost US consumers US$14.5 billion in additional egg expenditure — a level of disruption likely to recur without a vaccine strategy.

Over 169 million farm birds have been lost to HPAI in the US since February 2022, with 77% of losses concentrated in egg-laying hens. HPAI is now classified as enzootic (endemic) in North American wild bird populations — the seasonal October–February risk window is a recurring structural feature (CDC, March 2026). US consumers spent approximately US$14.5 billion more on eggs in 2024-25 than in prior years — roughly doubling the nation's annual egg expenditure — with egg prices at their March 2025 peak running 60% higher year-on-year.

FAO's January 2026 One Health Workshop (Singapore) confirmed H5N1 clade 2.3.4.4b remains globally active. Indonesia's dominant circulating strain remains a separate clade — indicating differentiated risk profiles across Southeast Asian poultry supply chains. US federal workforce reductions at key animal health labs have constrained outbreak response capacity. Pending legislation includes the Avian Flu Vaccination Strategy Act, but mass vaccination programmes face persistent market access barriers in key export markets.

Market Implications

• HPAI is no longer a periodic biosecurity event — it is a recurring structural cost embedded in North American poultry and egg supply chains
• The seasonal October–February risk window will recur annually without a commercial vaccine solution
• Food companies sourcing North American poultry inputs should treat HPAI as a standard annual supply risk scenario
• Export-dependent poultry markets, particularly in Southeast Asia, face differentiated but parallel biosecurity exposure
• The commercial and policy case for accelerated HPAI vaccine development is strengthening materially with each disrupted season

GFO Perspective

The CDC's endemic classification is a watershed moment for food industry supply chain planning. This is no longer a crisis to be managed reactively — it is a permanent structural feature of North American poultry production that requires integration into baseline supply chain models. The US$14.5 billion consumer cost in a single season, combined with constrained government response capacity, makes the case for commercial HPAI vaccination undeniable on economic grounds alone. Companies that continue to treat HPAI as an exceptional event rather than an annual supply variable are systematically underpricing their poultry input risk.